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1. INTRODUCTION 
 
 
1.1 STEM CELLS: DEFINITION AND GENERAL FEATURES 
The term “stem cell” was coined by the end of the nineteen century in order to name 
some cells supposedly involved in the continuous tissue renewal, such as blood 
renewal. 
During the last century uncountable scientific studies, as well as experimental 
evidences, have confirmed the existence of these cells, emphasizing their enormous 
and fascinating regenerative potential, so attracting on them a big interest of the 
scientific community for tissue engineering and other therapeutic applications. 
A stem cell is defined as unspecialized, able to multiply and renew itself indefinitely, 
and able to generate differentiated cells in response to specific stimuli. In order to do 
that, a stem cell goes through an asymmetrical division that gives rise to daughter 
cells, one of which is identical to the “mother cell” (self-renewal) while the other one, 
in response to microenvironmental stimuli, will produce term differentiated cells. 
This last described differentiative capacity is called potency: it can depend on stem 
cell origin and it is one of the parameters commonly used to classify stem cells. Stem 
cells classification can fall within four categories: Totipotent stem cells, Pluripotent 
stem cells, Multipotent stem cells and Unipotent stem cells. 
In mammals, only the zygote and its very early descendent cells can be defined 
totipotent stem cells because these cells are the only ones that possess the capability 
to give rise to all the specialized cells of the adult organism, and they can also 
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produce trophoblast derivatives (extraembryonic tissues and placenta) that support 
embryo growth. 
As embryonic development proceeds, cells start losing the over mentioned potential, 
retaining the ability to generate all types of cells derived from three germ layers but 
not the extraembyonic tissues. These cells will be classified as pluripotent stem cells. 
The last two stem cell categories (multipotent stem cells and unipotent stem cells) are 
tissue-resident stem cells that can respectively give rise to a certain number of cell 
types (e.g. hematopoietic stem cells) or to only one specialized cell type (e.g. 
melanocyte stem cells). In adult organisms, these cells play a role in supporting tissue 
renewal, regeneration and repair processes. 
Depending on their residency, stem cells can be also classified into embryonic, fetal, 
perinatal and adult stem cells.  
  
Figure 1: Stem cell potency (www.stemcellresources.org)  
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1.2 EMBRYONIC STEM CELLS (ESCs) 
Embryonic stem cells derive from the inner cellular mass of the blastocyst, during 
early developmental stages. 
Blastocyst appears as a spherical cyst composed by three main structures: 
- The trophoblast, that represents the peripheral portion of the blastocyst, whose 
function is to interact with the maternal environment. During the development, it will 
give rise to the placenta 
- The blastocoel, which is the fluid-filled central cavity of the blastocyst 
- The inner cell mass (ICM), a cluster of cells positioned at one end of the blastocoel 
which will give rise to all the embryonic tissues. ICM cells, that represent the source 
of the “embryonic stem cells”, are able to self-renew indefinitely, maintaining a 
normal karyotype and high levels of telomerase activity and they can give rise to the 
three embryonic germ layers (ectoderm, mesoderm and endoderm) as well as to all 
cell types of an organism [1-2]. 
ESCs are derived after blastocyst inner cell mass collection. Human cells may be 
obtained from donated frozen supernumerary embryos that result from in vitro 
fertilization (IVF). The main restrictions concerning embryonic stem cell research are 
related to ethical and safety issues [3]. For the first point, it is still questionable 
whether a zygote or an early stage embryo can be defined as “the very beginning of a 
life” because they have the remarkable potential to develop into a human being. For 
this reason some persons consider the use of embryonic cells for research or clinical 
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application as morally unacceptable and the Catholic Church is against embryonic 
stem cell research.  
In Europe stem cell research legislation and regulations are different from one 
country to another. In Italy, it is not possible to generate embryonic stem cell lines 
but it is permitted to use them for research only if they are imported [4]. 
The major safety issues concern teratoma formations. Teratomas are tumors made of 
a mixture of cells with different phonotypes that originate (in vivo and in vitro) as a 
consequence of a disorganized growth, due to the absence of correct environmental 
growth stimuli [5]. 
Based on the above mentioned reasons, alternative stem cell sources have been 
studied and proposed for stem cell-based therapies. 
  
Figure 2:  
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1.3 FETAL STEM CELLS (FSCs) AND PERINATAL STEM 
CELLS (PSCs) 
Fetal stem cells, as indicated by the definition, are stem cells located in fetal tissues 
such as bone marrow, blood, liver, pancreas, kidney and skin. FSCs are collected 
from tissues and organs mainly deriving from therapeuthical abortions, after mothers’ 
informed consent. 
Although their development potential is more limited than pluripotent ESCs, their 
high plasticity (multipotency) and replicative potential, as well as the lack of 
tumorigenicity, have made them one of the possible candidates for regenerative 
medicine applications and clinical uses (cell therapy)[ 6 ]. 
Fetal stem cell clinical applications [7-9] have been proposed as an useful tool that 
could promote tissue regeneration, providing a short-term “bridge” to organ 
transplantation, or as an option to treat some diseases such as Parkinson’s disease 
(human fetal dopaminergic neurons transplantation) [10-12]. 
Similarly to embryonic stem cells, FSCs isolation may give rise to ethical concerns 
but fewer restrictions are applied to their use. In Italy, there is no specific guideline 
regarding fetal stem cell research, but it is “generally regulated” by the law on organ 
donation and transplantation, after the mandatory informed consent is obtained. 
The most promising and available source of fetal stem cells are perinatal tissues [13] 
constituting the extra-embryonic structures of fetal origin: amniotic fluid, placenta 
and amniotic membrane, umbilical cord blood and umbilical cord matrix (Wharton’s 
jelly). 
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These structures are normally discarded after delivery and represent a precious source 
of stem cells, with high self-renewal potential and plasticity. Moreover, perinatal 
stem cells have a differentiation potential that could be considered slightly lower than 
ESCs, but higher than that of adult stem cells (ASCs). 
Similar to embryonic stem cells, PSCs express pluripotency markers such as Oct-4, 
whose function is to prevent precursor cells from differentiating, thus regulating stem 
cell self-renewal [14-15]. Other pluripotency markers shared with ESCs are NANOG, 
SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81 [16-19]. 
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Figure 3: Schematic representation of Placental structures. (Santrock J. W. Child 
Development,1998, , 8th edition, McGraw Hill) 
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1.3.1 AMNIOTIC FLUID STEM CELLS (AFSCs)  
Amniotic fluid is a protecting liquid that surrounds the fetus during pregnancy. It is 
composed by a heterogeneous cell population made of cells with variable capacity for 
self-renewal and differentiation, among which multipotent stem cells and terminally 
specialized cells (e.g. epithelial cells) could be indicated as the two opposite extreme 
examples. Amniotic fluid cells can be easily isolated from amniotic fluid specimens 
obtained, with informed consent signed by patients, for amniocentesis. 
One of the most attractive AFSCs population isolated, was found to be positive for 
the antigens Oct-4, SSEA-4, Nanog and CD117 (c-Kit) and for the mesenchymal cell 
markers CD105, CD90 and CD73 [20, 192-194]. Their multipotency (toward mature 
tissues of all the three germ layers) and high proliferative capability [20-21], make 
them good candidates for regenerative medicine applications. Limitations about 
AFSCs use reside in their low isolation rate (c-Kit positive cells are approximately 
1% of total amniotic fluid stem cells) [20]. 
 
1.3.2 PLACENTA AND AMNIOTIC MEMBRANE STEM CELLS 
Placenta for many years has attracted the interest of scientists because of its 
important role as intermediate structure mediating the fetal-maternal exchange of 
nutrients and gas and because of its involvement in maintaining immune tolerance 
between the mother and the fetus. 
During the last decade the attention of the scientific community has been directed to 
this organ as a source of progenitor stem cells for clinical applications. Placenta 
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consists of two portions: the chorionic plate (the fetal portion) and the basal plate (the 
maternal portion). Umbilical cord is attached near to the center of the fetal portion 
which is covered by fetal membranes (amnion and chorion). 
Two major stem cell populations can be isolated from placenta: chorionic 
mesenchymal stromal cells and chorionic trophoblastic cells [22] showing variable 
differentiation potential (e.g.osteogenic, adipogenic, chondrogenic). Moreover, an 
additional progenitor cell population, co-epressing mesenchymal and hematopoietic 
cell markers, was isolated from the decidua parietalis (belonging to the maternal part 
of the placenta) and characterized. 
The most promising progenitor cells isolated from term placenta are those isolated 
from the amniotic membrane, the amniotic stem cells. Amniotic membrane is made of 
three layers, the outermost consisting of mesenchymal cells (amniotic mesenchymal 
stromal cells, AMSCs, derived from the embryonic mesoderm), an intermediate 
membrane (lacking cellular components) and the innermost layer consisting of 
epithelial cells (amniotic epithelial cells, AECs, derived from the embryonic 
ectoderm). Both AMSCs and AECs populations express low levels of MHC (major 
histocompatibility complex) class I antigen and lack the expression of MHC class II 
molecules, suggesting their low immunogenicity [23-25]. This important property is 
also due to the expression of HLA-G, a non-classical MHC class Ib involved in the 
maintenance of tolerance between maternal immune system and fetus [26]. 
Approximately 10% of AECs express the stem cell markers Tra 1-60, Tra 1-80 and 
SSEA-4, and feature cellular plasticity [22,27-28]; conversely, amniotic 
mesenchymal stromal cells, possess a higher mesodermal differentiation potential 
 12
[29] compared to AECs. Since the beginning of the last century, whole amniotic 
membranes are used in clinic applications to treat burns and ulcers, as well as for 
corneal ulcerations [30]. 
1.3.3 UMBILICAL CORD and UMBILICAL CORD-DERIVED STEM CELLS 
Umbilical cord is the extraembryonic structure connecting placenta and fetus during 
the development. It represents the vehicle through which nutrients and oxygen are 
transported from the mother to the fetus. The UC is formed within the first weeks of 
gestation by the enclosure of the vessels (one vein and two arteries) into a bulk of 
mucous connective tissue, named Wharton’s jelly (WJ) and lined by the umbilical 
epithelium [31]. At term gestation, the umbilical cord appears as a 60-65 cm twisted 
tubular structure covered by an epithelium derived from the enveloping amnion and 
containing two arteries and one vein surrounded by the Wharton’s jelly. Cord 
twisting may occur due to discordant vessels' growth. The main function of 
Wharton’s jelly is to protect umbilical cord vessels from mechanical insults such as 
compression and torsion events. After birth, closure of the UC is an important and yet 
poorly understood process that safeguards against blood loss of the newborn.  
Wharton’s jelly is composed by proteoglycans, by collagen fibers and by 
heterogeneous, fibroblast-like cell populations, which were classically described as 
myofibroblasts.  Miofibroblasts are not defined either as fibroblasts or as smooth 
muscle cells despite the fact that they have muscle-specific cytoskeletal filaments. 
The term of “myofibroblast” was assigned because these stromal cells are positive for  
vimentin [32], a marker typical of fibroblasts, and desmin [33], a marker of muscle 
cells. The other fibroblast-like cells populating the Wharton’s jelly have instead 
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features similar to fibroblasts since they produce collagen and other extracellular 
matrix components. 
Even if the stroma can be divided into three different zones (subamnion, Wharton’s 
jelly and perivascular zone) and there are some differences between cells dispersed in 
these zones, the term ‘Wharton’s jelly cells (WJCs) is often extended to all umbilical 
stromal cells [31]. 
 
UMBILICAL CORD BLOOD STEM CELLS (UCSCs) 
Umbilical cord blood is being explored for use in regenerative medicine applications 
because it represents a rich source of hypo-immunogenic stem cells (mainly 
hematopoietic stem cells, HSCs) characterized by properties of proliferation and 
expansion greater than those of HSCs isolated from adult bone marrow (BM), which 
currently still represents the major source of stem cells [34-36].  
Another advantage of UCSCs use is that cord blood collection is not at all an invasive 
procedure, it is painless and free of risks for both mother and baby. Moreover, UCSC 
showed a reduced risk of graft-versus-host disease (GVHD) mainly due to the more 
immunologically immature (naïve) nature of T cells derived from cord blood with 
respect to those isolated from adult tissues and, consequently, also more tolerant to 
HLA tissue mismatching [37-39]. Limitations to cord blood applications are related 
with problematic engraftment kinetics compared to BM-derived cells. 
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UMBILICAL CORD MATRIX (WHARTON’S JELLY) STEM CELLS 
Wharton’s jelly mesenchymal stem cells (WJ-MSCs) are multipotent fibroblast-like 
cells involved in collagen and extracellular matrix component production. They were 
first isolated more than 10 years ago [40] and they were shown to provide secretion 
of mucopolysaccharides, glycosaminoglycans and extracellular matrix proteins that 
constitute the bulk of umbilical cord matrix. As stated earlier, WJ-MSCs have been 
isolated from three umbilical cord regions - the perivascular zone, the inter-vascular 
zone and the sub-amnion – showing rough differences in phenotype and 
differentiation potential depending on the WJ compartment from which they are 
derived [41-42]. 
During the last decade the immunophenotype of WJ-MSCs has been extensively 
studied by several researchers that have demonstrated an antigenic pattern resembling 
that of mesenchymal stem cells originated from other tissues. 
In accordance with “minimal criteria” estabilished by the Mesenchymal and Tissue 
Stem Cell Committee of the International Society for Cellular Therapy for defining 
mesenchymal stem cells, and similarly to bone marrow mesenchymal stem cells 
(BM-MSCs), WJ-MSCs express CD105, CD73 and CD90 antigens but lack the 
expression of endothelial (CD31) and hematopoietic markers (CD45, CD34) [44]. 
Both WJ-MSCs and BM-MSCs also express CD29, CD166, CD44, CD10, CD13 and 
HLA class I [45-49] but do not express HLA-DR [50-53]. 
Furthermore, these cells are positive for mesodermal markers such as α-smooth 
muscle actin and vimentin, and for antigens expressed by cells of different tissues 
(e.g nestin, connexins, stem cell factor), so allowing the hypothesis of an intrinsic 
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multilineage differentiation capability. Nestin is an intermediate filament protein first 
identified in rat neuro-epithelial stem cells. Subsequently it was found to be 
expressed by various precursor cells such as beta cell progenitors or hepatic oval cells 
[54-55]. Other neuronal markers expressed in WJ-MSCs are: glial fibrillar acidic 
protein (a neuroectodermal marker) and neuron-specific enolase [56-57]. 
Connexins are integral membrane proteins involved in intercellular gap junctions. In 
particular, connexins 40, 43 45 [58-59], typically found in cardiomiocytes, have been 
demonstrated by our laboratory to be expressed by WJ-MSCs. 
Moreover, a possible hepatic differentiation potential was first indicated by the 
expression of cytokeratins (CK8 and CK18) and hepatocyte nuclear factor 4α (HNF-
4α) [58] and then recently confirmed by our group (Lo Iacono et al. manuscript in 
preparation). HNF-4α is indeed a transcription factor necessary for the maintenance 
of hepatic functions [60-61], inducing the expression of many genes, some of which 
play an important role in lipids and glucose metabolisms [62-63]. HNF-4α is also 
involved in insulin expression and secretion activities in beta cells [64-65]. This is 
due to the sharing of a common embryonic origin between liver and pancreas, as both 
are derived from almost the same regions of the primitive endoderm. This 
spontaneous expression of all described differentiation markers strongly suggests that 
WJ-MSCs are prone to differentiate toward several cellular types. 
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WJ-MSCs differentiation capability.  
In accordance with the minimum criteria defined by International Society for Cellular 
Therapy [44], they are able to differentiate into mesodermal cell types including 
chondroblasts, osteoblasts and adipocytes. Moreover, their ability to differentiate into 
muscle cells, cardiomyocytes, glial and endothelial cells has been demonstrated by 
several reports indicating umbilical cord matrix as a promising stem cell source for 
regenerative therapies. 
Cardiac differentiation: WJ-MSCs can be differentiated into cardiomiogenic 
lineages, as demonstrated by the acquisition of a specific morphology and by the 
expression of cardiac specific markers, such as connexin 43 and cardiac troponin I, 
following stimulation with 5-azacytidine for 21 days [49]. In addition, WJ-MSC 
therapeutic potential in cardiovascular tissue engineering application has been 
suggested [66]. 
Skeletal muscle differentiation: WJ-MSCs hve been also demonstrated to give rise to 
skeletal myocytes in response to myogenic culturing conditions [67]. 
Chondrogenic differentiation: Chondrogenic potential of WJ-MSCs was also reported 
by my research group, indicating the possible use of these cells as a future treatment 
for articular diseases [68-69]. 
Endothelial differentiation: WJ-MSCs can differentiate into endothelial-like cells, as 
demonstrated by both morphological and physiological changes [70]. 
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Neural differentiation: WJ-MSCs can give rise to Schwann cells that, once 
transplanted into rats transected sciatic nerve were able to support in vivo functional 
recovery [71-72]. 
Hepatic differentiation potential: Recent data showed that WJ-MSCs can also 
undergo hepatocyte differentiation. Campard and al. demonstrated that these cells can 
differentiate into hepatocyte-like cells, by culturing them in a medium containing 
hepatic growth factors [73]. The initial cell population was positive for the expression 
of cytokeratins 8, 18 and 19 but negative for cytokeratin 7; the expression of α-1-
antitrypsin, tryptophan 2,3-dioxygenase and Glucose-6-Phosphatase was also 
demonstrated but not the positivity for Hepatocyte specific antigen-1 (HepPar1), 
HNF-4α (Hepatocyte nuclear factor 4 alpha) or for the isoform 3A4 of the 
cytochrome p450. 
The hepatocyte-like cells derived from the induction process increased the expression 
of some hepatic-specific markers such as tryptophan 2,3-dioxygenase, but remained 
negative for HNF-4 α and HepPar1, questioning the acquisition of a mature 
phenotype, and therefore highlighting the necessity of further improvements of the 
differentiation protocol [74]. Despite that, a functional maturation was achieved as 
demonstrated by several assays that quantify hepato-specific abilities such as urea 
production, Glucose-6-Phosphatase activity, CYP3A4 induction and glycogen storage 
capability. 
Hepatic differentiation was also demonstrated in vitro by Zhang and co-workers [75] 
applying a one-step protocol. HGF and FGF-4 stimulation resulted in liver-specific 
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markers expression, such as albumin and alpha-feto protein, by treated cells. 
Moreover stored glycogen and uptake of LDL was also demonstrated 
In vivo experiments strongly supported future application of WJ-MSCs for liver 
regenerative medicine. Published data showed the acquisition of hepatic markers 
expression by undifferentiated WC-MSCs, following transplantation, in liver of SCID 
mice following partial hepatectomy [73].  
In addition, a supportive role of naïve Wharton’s jelly mesenchymal stem cells in 
rescuing injured liver functions and in reducing fibrosis was also demonstrated by 
Tsai and colleagues in a rat model ofhepatic injury and fibrosis induced by CCl4. WJ-
MSC-infused rats showed reduced levels of serum transaminases, as well as a 
reduction of TGFβ1 and α-SMA if compared to control groups. These data nicely 
correlated with an overall reduction of liver fibrosis [76]. These data support the 
hypothesis that undifferentiated mesenchymal stem cells may favor the functional 
recovery of recipient livers, perhaps inducing the differentiation of endogenous liver 
cells and by enhancing fibrous matrix degradation [77]. 
Moreover, recent data from another work by Yan and collaborators demonstrated the 
effects of WJ-MSCs engraftment in livers of CCl4-injured mice. Interestingly, 
compared with control group, mice that received WJ-MSCs administration showed a 
reduction of apoptosis together with an increase of hepatocytes proliferation [78]. 
Finally, Zhao and collaborators [79] showed that hepatocyte-like cells derived from 
WJ-MSCs following hepatic differentiation, expressed hepatic specific antigens and 
also maintained in vitro hypoimmunogenicity features (lack of HLA-DR expression). 
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These data are very interesting and demonstrated that the differentiative process did 
not interfere with the immunological features of these cells.  
 
Immunomodulatory properties of WJ-MSCs 
As demonstrated for mesenchymal stem cells isolated from different tissues (such as 
adipose and bone marrow), many scientific publications have also reported the 
expression of immunomodulatory and tolerogenic molecules by WJ-MSCs, such as 
not classical HLA class I molecules (HLA-E, HLA-F and HLA-G) [80-82], CD274 
and CD276 (belonging to B7 family of molecules) [80, 83-84], as well as leukaemia 
inhibitory factor (LIF) [85]. In addition, the lack of expression of HLA-DR and the 
absence of CD80 and CD86 costimulatory antigens [58, 86] (commonly involved in 
acceptance or rejection of transplanted organs), strongly suggests the capability of 
these cells to regulate immune cells activation and proliferation. 
In vitro analyses of MHC molecules expression by stem cells is of fundamental 
interest because it gives important suggestions regarding the way these cells could act 
once transplanted in vivo. As also commented in other sections of the present thesis, 
WJ-MSCs low immunogenicity is due to the absence of HLA-DR molecules whereas 
tolerogenic features can be mainly explained by the presence of B7-H3 molecules as 
well as by the expression of class Ib HLA molecules (HLA-E and HLA-G). HLA-G 
and HLA-E were initially characterized on extravillous trophoblast, where both act as 
molecules protecting fetus form maternal allorecognition during pregnancy. To date it 
is known that these molecules are also expressed in different districts and that they 
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exert multiple immunoregulatory functions by acting as ligands for inhibitory 
receptors present on NK cells and macrophages. 
HLA-G exists as a membrane-bound molecule and as a secreted isoform (HLA-G5), 
thus exerting its immunomodulatory function through two different mechanisms. It 
has also been suggested that HLA-G could explicate their immunomodulatory 
function by activating T regulatory cells (Tregs), known to be key suppressors of 
effector responses to alloantigens [87]. 
 
1.4 ADULT STEM CELLS (ASCs) 
 
Adult stem cells are classically defined as multipotent stem cells that are thought to 
reside in a quiescent state into specific areas of multiple tissues and organs after birth 
called “niches”, representing cellular microeviroments that provide specific stimuli 
necessary for survival, proliferation, migration and differentiation events. 
ASCs primary function is to maintain tissue homeostasis and they are mainly 
involved in tissue repair processes following traumatic events or diseases of different 
nature. Even if they appear to have a more restricted differentiation potency and self 
renewal ability compared to embryonic or perinatal stem cells, there are many 
advantages that suggest their use over other cell categories. For example, ASCs do 
not form teratomas, there are no ethical concerns on their use and these cells can be 
easily used for autologous transplantation with no need of immunosuppression. 
Conversely, depending on tissue origins, adult stem cells are sometimes difficult to be 
isolated (e.g. hepatic precursor cells) and expanded, resulting in a very low cellular 
yield and the limited differentiation potential imply a reduced applicative potential if 
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compared to embryonic stem cells. Moreover, these cells are very difficult to be 
maintained in culture in undifferentiated state. 
Even if for many years ASCs were thought to have a tissue-specific differentiation 
capability, recently an increasing numbers of reportes have demonstrated that these 
cells are able to give rise to cells of different origins, introducing the concept of 
“adult stem cell plasticity”, defined as the ability of these cells to trans-differentiate 
into cells of different lineages.  
This phenomenon is still not entirely clear and can be explained by different potential 
mechanisms: cell fusion, trans-differentiation, de-differentiation or pluripotency [88]. 
During cell fusion events, stem cells acquire the phenotype of the tissue they are 
transplanted within; this phenomenon is not so common and has been reported for 
bone marrow stem cells transplanted into organs such as the liver [89]. Trans-
differentiation occurs when silent genes involved into other differentiation programs 
are activated, transforming cells into different cellular types. De-differentiation is a 
phenomenon during which cells spontaneously lose differentiated features, acquiring 
a more immature state and, subsequently differentiate again into diverse cell lineages. 
Finally, the presence of pluripotent stem cells residing into different niches has been 
demonstrated in many tissues. Some examples of stem cell plasticity are represented 
by bone marrow hematopoietic stem cells trans-differentiation into muscle cells [90]; 
moreover neuronal stem cells and stem cells isolated form muscle tissues were able to 
reconstitute the hematopoietic system in rodents [91-92]. As an additional example, it 
has been reported that bone marrow derived cells were induced to differentiate into 
neuron-like cells [93-94].  
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The two major adult stem cell families are represented by Hematopoietic Stem Cells 
(HSCs) and Mesenchymal Stem Cells (MSCs), the both of them expressing 
embryonic stem cell markers such as OCT4, SOX2, NANOG, LIN28, SSEA-1, 
SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 [95-99]. Hematopoietic stem cells are 
the most studied stem cells and they also have been effectively and extensively used 
for patients with chronic myeloid leukaemia or after high-dose chemotherapy to 
restore blood cell production, remaining an effective treatment for patients with 
certain haematological diseases. Even if initially HSCs were thought to have a 
reduced plasticity (limited to blood and blood derived cells) a recent review 
summarizes many scientific publications demonstrating that these cells can 
differentiate into almost all cell types [100]. 
 
Figure 4: Examples of adult stem cells. (Picture taken from http://stemcells.nih.gov).
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1.5 MESENCHYMAL STEM CELLS (MSCs) 
 
Figure 5:  MSCs multipotent-capacity (Tracey L Bonfield et al, Discovery Medicine April 15, 2010) 
 
Mesenchymal stem cells are multipotent progenitor cells originating from neural crest 
and mesoderm during embryogenesis [101-102] that reside within the stromal 
fraction of adult bone marrow where they are involved in non-hematopoietic stromal 
cell renewal.  Even if MSCs reside in most tissues and can be easily derived from 
them, to date bone marrow represents the primary source of mesenchymal stem cells 
(bone marrow aspirates). These fibroblast-like cells in standard culture conditions 
grow adhering to plastic, are characterized by an extensive self-renewal capability 
and they also have a multi-lineage differentiation potential, being able to differentiate 
into mesodermal cell types such osteoblasts, chondroblasts and adipocytes [44, 103-
104]. In addition, MSCs have also been demonstrated to have the potential to 
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differentiate into cells normally derived from endoderm or ectoderm (e.g. neuronal- 
like cells, cardiomiocytes or hepatocyte-like cells) [105-109] indicating an interesting 
versatility of these cells.  
Because of all these properties, together with their hypoimmunogenicity (the absence 
or low level of expression of MHC class II antigens and costimulatory molecules 
such as CD80, CD 86 and CD40 limit immune-recognition) and immune-regulatory 
features, mesenchymal stem cells have often been considered an ideal cell source for 
stem cell based therapies and regenerative medicine applications, allowing 
therapeutic applications of both autologous and allogeneic MSCs in the clinical 
setting. 
Tolerogenicity has also been associated with the expression of HLA-G antigen, a non 
classical major histocompatibility complex class I molecule, that represents a potent 
tolerogenic molecule reported to contribute to the regulation of immune responses in 
both physiological (e.g. playing a crucial role during fetal-graft tolerance via the 
maternal immune system [110]) and pathological conditions (such as cancer, multiple 
sclerosis and inflammatory diseases [111-113]). 
MSCs immune-regulatory properties have been demonstrated on a wide range of 
immune system cells [114-119] by in vitro and in vivo experiments and this 
interesting and complex phenomenon, that it is still not fully understood, has been 
explained by direct cell to cell contact as well as by the action of several bioactive 
molecules and factors such as indolamine 2,3 dioxygenase (IDO), interleukin (IL)-6, 
nitric oxide (NO) and prostaglandin (PGE)-2 [119-122], and also the soluble isoform 
of HLA-G, named HLA-G5 [123]. 
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MSCs for therapeutic applications: 
A recent research of the clinical trials database (www.clinicaltrials.gov) showed 375 
mesenchymal stem cells clinical trials all around the world (Figure 6), which make 
use of these cells to treat a wide range of pathological conditions or diseases (e.g. 
graft-versus-host disease, autoimmune diseases, bone diseases, liver and 
cardiovascular diseases). Most of the recorded clinical trials are in Phase I or Phase 
II. The results collected so far indicate that MSCs are mostly well-tolerated, with very 
few adverse effects; moreover, many of them showed the efficacy of mesenchymal 
stem cell infusions in treating stroke, liver cirrhosis and acute myocardial ischemia. 
 
 
Patients, 
number 
Source of 
MSCs 
MSCs 
Phenotype 
Cells 
infused 
Dosage Adverse 
effects 
Follow-
up 
Outcome Reference 
Stroke, 16 Autologous 
iliac crest 
90% SH2 5 × 107 
twice 
2 doses,  
2-week 
interval 
None To 5 
years 
HR for 
MSCs = 
0.344 
[125] 
MI, 10 Autologous 
iliac crest 
CD73+ 
CD90+ 
CD105+ 
7.5 × 106 
MSCs + 
EPCs 
1 dose None 6 
months 
LVEF 
12% up 
[126] 
MI, 53 Allogeneic 
unmatched 
'prochymal' 
CD105+ 
CD166+ 
CD45 
0.5 to 5 × 
106/kg 
1 dose, 
intravenous 
MSCs 5 
pt 
Placebo 7 
6 
months 
FEV1 up, 
LVEF up, 
arrhythmi
a down 
[127] 
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ALS, 10 Autologous 
iliac crest 
CD29+ 
CD44+ 
CD90+ 
CD105+ 
CD166+ 
11.4 to 
120 × 106 
1 dose, 
thoracic 
spine 
None 4 years MSCs 
tolerated, 
SC scars 
[128] 
ALS, 19  
MS, 15 
Autologous 
iliac crest 
CD29+ 
CD73+ 
CD90+ 
CD105+ 
CD166+ 
ALS  
5 × 107 
MS 6 × 
107 +/- 
ferumoxid 
1 dose, 
intrathecal 
1 dose, 
intravenous 
None 6-25 
months 
ALSFRS 
stable, 
EDSS 
better 
[129] 
Refractory 
Crohn's 
Disease, 10 
Autologous 
iliac crest 
CD73+ 
CD90+ 
CD105+ 
1 to 2 × 
106/kg 
2 doses,  
1-week 
interval 
Headache 
(3 
patients) 
Allergy  
(1 patient) 
14 
weeks 
CDAI fall 
(5 
patients; > 
70 in 3 
patients);3 
patients 
worse 
[130] 
Paediatric 
acute 
leukaemia, 8 
Haploid 
parent BM 
Adherent 
CD 
phenotype 
ND 
6 × 104 to 
107/kg 
MSCs + 
UCBT 
1 or 2 doses, 
3-week 
interval 
None 6.8 
years,  
no 
chronic 
GVHD 
All 
patients 
PMN+ at 
9 to 28 
days 
[131] 
Table 1: Examples of recent MSCs clinical trials [124] 
Table 1 abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS, ALS Functional Rating Scale; 
BM, bone marrow; CDAI, Crohn's disease activity index; Con, control; EDSS, Expanded Disability 
Status Scale; EPC, endothelial precursor cell; FEV1, forced expiratory volume in 1 second; GVHD, 
graft-versus-host disease; HCT, haematopoietic cell transplant. HR, hazard ratio; LVEF, left 
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ventricular ejection fraction; MI, myocardial infarction; ND, not determined; PMN, 
polymorphonuclear leukocyte (surrogate for HSC engraftment); SC, spinal cord; UCBT, umbilical-
cord blood transplant (unrelated). 
 
Even if MSCs administration efficacy is not fully understood, it is widely accepted by 
the scientific community that four MSCs properties mainly contribute to their 
therapeutic/reparative effectiveness:  
1) MSCs multipotency. 
2) Mesenchymal stem cell hypo-immunogenicity and their immunomodulatory 
properties. 
3) MSCs capacity to home to inflammatory or injured sites once injected in a host, 
irrespectively of the tissue (e.g lung or muscle tissue in mice [132-133]), in response 
to signals released by damaged tissues. 
4) Anti-inflammatory properties associated with bioactive molecules secreted by 
mesenchymal stem cells in response to their local environment. 
There are two main restrictions that limit the use of BM-MSCs: the invasive nature of 
the collection procedure and the progressive cell number decline from birth (where 
one mesenchymal stem cell is found per 104 cells) to adults, due to age-related 
alterations and replicative decline probably due to changes occurring at the level of 
the biological niche as a consequence of modified micro-environmental signals [134]. 
Consequently, more accessible sources of MSCs are desirable and these alternative 
stem cell sources could be represented by perinatal tissues, ready available and whose 
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isolated MSC are suggested to have a higher proliferative and differentiative potential 
over bone marrow derived ones. 
 
 
 
 
  
Figure 6: Mesenchymal stem cells clinical trials distribution worldwide       
(www.clinicaltrials.gov) 
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1.6 STEM CELLS AND HEPATIC REGENERATION 
1.6.1 ANATOMY AND FUNCTIONS OF THE LIVER 
The liver represents the largest solid organ of the human body and it plays a central 
role in metabolic homeostasis (lipid, carbohydrate and protein metabolism), 
participating in the synthesis, distribution and storage of many nutrients and 
metabolites. It is responsible of body detoxification and drug xenobiotic metabolism, 
via conjugation or metabolic modification processes. 
As a gland, it exerts both exocrine function (bile production and secretion) and 
endocrine function (synthesizes chemicals and plasmatic proteins that are secreted 
directly into the blood regulating the functions of many other organs). 
 
Figure 7: Liver Anatomy (taken from “The Johns Hopkins Atlas of Human Functional Anatomy 
4th Edition”) 
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The liver is located in the right and upper portions of the abdomen, beneath the right 
side of the diaphragm and under the right lower rib cage. The liver is mostly covered 
by the peritoneum and it has two surfaces: the parietal surface, and the visceral 
surface. The “classical description” of the liver anatomy considers the falciform 
ligament as dividing the parietal surface of this organ into a larger right lobe (that 
roughly represents 60-65% of the liver) and a left lobe. The visceral surface contains 
also the quadrate and caudate lobes [135]. 
Each hepatic lobe is composed of the lobules that traditionally have been considered 
as liver morphofunctional units (Figure 8). Each lobule resembles an irregular 
polygonal prism with a central vein in the middle of it and “portal spaces” at each 
corner. 
In each lobule flat irregular plates of hepatocytes, separated by hepatic sinusoids, 
radiate from the central vein area towards periphery. The blood capillaries convey the 
blood centripetally from the periphery of the lobule (terminal branches of the hepatic 
artery and portal vein) to the central vein, while the bile flows centrifugally towards 
the portal areas. 
Hepatocytes represent the main lobule cell type (80% of the total liver mass). They 
are large polyedric cells containing a big rounded nucleus (25% of these cells contain 
two nuclei), approximately 2000 mitochondria, abundant rough endoplasmic 
reticulum (albumin, prothrombin, fibrinogen and globulin synthesis) and smooth 
endoplasmatic reticulum (involved in detoxification or inactivation processes of 
various substances such as water-insoluble toxic bilirubin). 
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The remaining liver resident cells (20%) include Kupffer cells, Ito cells (fat-storing 
cells), stellate cells, natural killer (NK) cells, endothelial cells and cholangiocytes. 
Kupffer cells are large mononuclear phagocytic cells derived from blood monocytes 
(representing approximately 70% of the total macrophage population of the body), 
involved in several processes such as bacteria and inflammatory mediator scavanging, 
phagocytosis of damaged or aged red blood cells and hemoglobin digestion [136]. 
A more modern perspective coniders the hepatic acinus to be the smallst functional 
comprising part of two adjacent hepatic lobules; the narrower ends are formed by two 
central veins, while the central wider portion is formed by two paortal areas. Even if 
the acinus better defines the hepatic functional unit, it is not so easy to be visualized 
by histology. 
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Figure 8: The hepatic lobule is roughly hexagonal in shape. The angles of the hexagon are 
called portal tracts (or portal areas). Hepatocytes are arranged in stacks of anastomizing 
plates, radiating from a centre of the lobule (central vein) towards the periphery. Hepatocyte 
plates are separated by an anastomizing system of sinusoids. 
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1.6.2 LIVER RIGENERATION  
The extraordinary liver regeneration ability (after injury or upon surgical resection) 
has been known since classical times [43]. This phenomenon is made possible 
through proliferation of pre-existing mature hepatocytes that, in spite of their slow 
cell turnover rate, are able to regenerate hepatic tissue in response to tissue lesions. 
This important and complex regenerative process has to be considered as a 
compensatory process aimed to restore the number of functional hepatocytes 
necessary for the maintenance of body homeostasis.  
Liver regeneration events that take place during the first 4-5 hours following partial 
hepatectomy (70% hepatectomy, HP) are often referred as “priming phase events”, 
and they involve stress and inflammatory responses (cytokine production and 
release), transcription factor activation/generation (e.g. NFK-B, CIEBPP,  STAT3 
and AP-1) [137-141] extracellular matrix modifications (activation of 
metalloproteinase 9 within the first 30 minutes) [142-143] and regulatory events for 
cell-cycle entry (activation of almost 100 genes that directly or indirectly are involved 
in cell cycle entry and progression) [144]. The chronology of the very early signaling 
events after partial hepatectomy is summarized in Table 2. 
Stat3 and NF-kB are important signaling molecules contributing to hepatocyte 
proliferation. Immediate early and delayed gene expression is not sufficient to reach 
DNA replication unless the hepatocytes progress through the cell cycle, progression 
sustained by growth factors such as transforming growth factor alpha (TGF-α) and 
hepatocyte growth factor (HGF) [145]. Once this restriction point is passed, 
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hepatocytes express cyclin Dl (at 6 hours there is clear evidence for of cyclin D1 
activation) andcells are irreversibly committed to replication process [146]. 
When pathological conditions or extended hepatic injuries are so severe to 
compromise hepatocyte regenerative capability (as in chronic hepatopathy, viral 
hepatitis or hepatic steatosis), hepatic stem cells are activated. These cells (named 
oval cells in rats and mice) are liver progenitors characterized by ovoid nuclei and 
high nuclear/cytoplasmic ratio; these bipotential stem cells reside within the liver’s 
terminal branches of the biliary tree (canals of Herring) and can give rise to bile duct 
cells or hepatocytes. In humans, oval cells were identified in several liver diseases 
such as hepatitis B-associated hepatocellular carcinoma, hepatoblastoma and in 
cholestatic liver diseases [147-149]. The lack of unique liver stem cell markers has 
posed significant challenges to the identification and isolation of the ‘true’ liver stem 
cell. 
Oval cells express hepatocyte (albumin, alpha-fetoprotein, cytokeratins CK8 and 
CK18) and cholangiocyte (CK7, and CK19) markers and they also express some 
progenitor markers (OV-6 in rats, chromogranin A in humans) [150-153]. Moreover, 
these cells are positive for some hematopoietic stem cells markers (CD34, CD45, 
CD90, Sca-1, c-Kit, and flt-3) [150,154]. Under physiological conditions, these cells 
are few and quiescent; in response to hepatic injuries oval cells start to proliferate, 
modify their morphology and surface markers and start to differentiate to compensate 
liver mass loss. 
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Differently from rats, human bipotent progenitor cells express EPCAM (epithelial 
cell adhesion molecule), NCAM and do not express alpha-fetoprotein and albumin 
[155-163]. 
 
TABLE 2: Early signaling events activated followingpartial hepatectomy(from George K.  
Michalopoulos Liver Regeneration J Cell Physiol. 2007 November; 213(2): 286–300.)  
Multiple signaling pathways involving growth factors, cytokines, paracrine signals, 
and neuroendocrine factors occur simultaneously within the first 60 min after partial 
hepatectomy (PH). These include: 
• Increase in urokinase activity (first 5 min) 
• Translocation of Notch to the nucleus (15 min) 
• Translocation of beta-catenin to the nucleus (5–10 min to 6 h) 
• Decrease in HGF biomatrix stores (30 min to 3 h) 
• Activation of the HGF receptor (within 30–60 min) 
• Activation of the EGF receptor (within 30–60 min) 
• Increase of HGF, Norepinephrine, IL6, TNFa, TGFb1 and hyaluronic acid in the plasma (1–2 h) 
• Activation of AP1, NFkB, and STAT3 (30–60 min) 
• Extensive gene expression reprogramming of hepatocytes within 30 min after PH 
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1.6.3 THERAPEUTIC POTENTIAL AND CLINICAL APPLICATIONS OF 
CELL THERAPY FOR LIVER DISEASES 
 
In spite of liver unique regeneration potential, in case of advanced end-stage liver 
diseases this capability is not enough to reestablish a sufficient liver mass and, 
consequently, to adequately restore liver homeostasis and hepatic functions.  
To date, liver transplantation represents the only life-saving procedure for liver 
pathologies such as alcoholic liver disease, primary liver cancer and 
haemochromatosis, hepatitis C and B infections (that represent the major liver 
diseases); during the last decades it has been registered a dramatic increase of the 
number of human liver transplants but the demand greatly exceeds organ availability.  
In U.S. 20,000 people wait for liver transplantation, but less than 1/3-1/4 of needed 
transplants are performed annually, therefore more than a hundred patients die yearly 
while on the waiting list.  
Furthermore, it has to be said that liver transplantation benefits are hampered by 
many disadvantages, such an increased risk of infection, post transplant rejection, 
biliary conditions and a higher risk of developing type 2 Diabetes. All these issues 
have lead researchers to propose and develop new approaches as alternative therapies 
for intractable liver diseases; specifically, in recent years, scientific community has 
been giving increased attention to cell therapy to treat liver insufficiency or end-
staged liver diseases, and that could be used as a bridge to liver transplantation. 
Proposed approaches can be broadly divided into two categories: transplantation of 
endogenous cells (mature hepatocytes or hepatic committed stem cells) and strategies 
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involving extra-hepatic stem cells (mainly mesenchymal stem cells and hematopoietic 
stem cells). 
Strong scientific evidences have demonstrated therapeutic efficacy of allogeneic 
hepatocyte transplantation, particularly to treat liver based metabolic disorders such 
as Crigler-Najjar Syndrome type I, ornithine-transcarbamylase deficiency and 
coagulation factor VII deficiency [157-160]. Moreover, Khan et al. completed a 
clinical trial based on human fetal liver stem cell transplantation in patients with end-
stage liver cirrhosis, demonstrating the safety and efficacy of this procedure [161]. 
On the other hand the limited availability of human organs for hepatocyte isolation 
and short term effects of the therapy (from few days to few months for acute liver 
injuries) represent the major limits to this procedure. 
Another alternative endogenous cell source for transplantation is represented by 
previouslydescribed hepatic progenitor cells. These cells can be easily isolated from 
liver of all donor ages and extensively expanded (more than forty population 
doubling) under serum free conditions, demonstrating a high expansion potential 
[162-164]. 
In India clinical trials involving fetal liver derived EpCAM positive stem cells have 
been conducted, resulting at 6-month follow-up into a significant decrease in the 
mean of MELD SCORE and minimal immunological issues have been proved. 
Notably, patients enrolled for the trials had an original life expectancy of 5-6 months 
[161, 165-166]. 
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Preliminary results regarding ongoing clinical trials with hepatic stem cells 
(EpCAM+) and adult hepatocyte transplantation can be summarized as follow [167]: 
Hepatic Stem Cells (isolated from fetal 
livers) 
 
Cell number tested ranged between 100-
150 milion 
 More than 280  patients involved in trials 
 No complication from transplanted 
procedure (delivery via hepatic artery) 
 Immunosupression not required 
 Engraftment efficiencies were around 
20% 
 Long term effects (more than 4 years) 
 Significant improvement in MELD or 
Child-Pug Scores and in all measured 
liver functions 
TABLE 3: Fetal stem cell clinical trials 
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Adult hepatocyte transplantation (cells 
isolated from neonatal, fetal or adult 
livers) 
Number of cells transplanted: from few 
hundred million to billions 
 Complications related with transplant 
procedure (delivery by vascular route 
into portal vein) such as emboli 
formation 
 Immunosuppression required 
 Significant improvement in measures of 
liver functions 
 Transitory effects ranged from few 
month to few years for patients with 
methabolic disorders and from few days 
to few years for acute liver injuries 
TABLE 4: Adult hepatocyte clinical transplantations 
 
In a context in which it is still a matter of debate as to which adult stem cell 
population may be the most effective in the regeneration of injured liver tissues, 
hematopoietic and mesenchymal stem cells have emerged as two of the major 
candidates, because of their differentiation capability into hepatocyte-like cells in 
vitro (in presence of HGF, FGF and oncostatin M) and in vivo [89, 168-170]. 
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It has been reported that hematopoietic stem cells (HSCs) can differentiate into 
hepatocyte in case of liver injuries/established liver fibrosis (animal models) [168-
169, 171]. HSCs have also been used in clinical trials as a treatment for liver diseases. 
In two of them [172-173], the effects of whole bone marrow peripheral infusion and 
of CD34+ HSCs intrahepatic injection have been assessed in nine and five cirrhotic 
patients respectively. The results of these two studies indicate that bone marrow stem 
cell transplantation resulted in an increased hepatic function (e.g. significant 
improvement of albumin levels) in a number of cirrhotic patients; however, both 
analyses were conducted on patient groups that were too small to be representative of 
the population. 
A clinical investigation involving a larger group of patients with end-stage liver 
cirrhosis (140 patients) was conducted in Egypt by Salama et al. [174]. Patients were 
randomized into two groups: a control group (receiving regular treatment) and a 
second group receiving granulocyte colony stimulating factor followed by autologous 
CD34 (+)/CD133 (+) hematopoietic stem cell infusion in the portal vein. The results 
obtained by this group were consistent with the data published by the other two 
groups in terms of significant improvement of albumin and bilirubin levels in the 
transplanted patients compared to the control group, as well as safety and tolerability 
of the procedure. 
In the last few years MSCs, isolated from several tissues, have emerged as elective 
candidates for cell transplantation since they are abundantly resident in almost all 
tissues, can be easily isolated, and due to their multipotency and regenerative 
outcome in animal models, as well as their immunomodulatory properties. 
 41
MSCs capability to differentiate into hepatocyte-like cells was first described in 2004 
[109] and MSCs trans-differentiation was subsequently demonstrated through several 
scientific reports, indicating the acquisition of hepatocyte-like features (described 
earlier) [173, 175-178]. 
To date, more than twenty clinical trials involving MSCs infusions (unfractionated 
bone marrow derived MSCs, bone marrow CD34/CD133 positive cells or MSCs pre-
differentiated into hepatocyte-like cells)  to treat cirrhosis or acute liver failure have 
been published (www.clinicaltrials.gov). Even if long term effects were not observed, 
safeness and liver function improvements have been reported.  
In general it has to be said that so far many aspects such as cellular characterization 
(in some cases) or a better understanding of in vivo MSCs action that allow clinical 
improvements need to be better characterized, and randomized controlled studies are 
needed. 
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2. AIMS OF THE STUDY 
Over the last decade, multiple evidences have highlighted the attractive therapeutic 
potential of perinatal mesenchymal stem cells making them promising candidates for 
tissue engineering and regenerative medicine applications. In particular, our group 
has demonstrated that multipotent Wharton’s Jelly Cells (WJ-MSCs) can be easily 
isolated and successfully expanded in vitro from human umbilical cord. These cells 
have the potential to be committed towards different tissues and, recently, 
immunomodulatory features were also demonstrated by us and others.  
Preterm cords can be made available from therapeutic abortions, constituting an 
additional cell source to obtain higher numbers of WJ-MSCs. Little is known about 
the phenotype and the differentiation potential of these cells. 
Our hypothesis is that WJ-MSCs isolated from preterm umbilical cords, because of 
their more immature state, could have a greater differentiation potential than the ones 
isolated from term umbilical cords and may be proposed as additional stem cells that 
can be used for regenerative medicine applications. 
The following objectives were designed to test the hypothesis:  
 
Aim 1: Determine if preterm WJ-MSCs can be isolated and cultured using the 
protocols previously described by my group for mature umbilical cords.  
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Aim 2: Define a detailed phenotypic characterization of preterm WJ-MSCs using 
flow cytometry, immunocytochemistry and immunofluorescence analyses. 
 
Aim 3: Evaluate mesenchymal multi-lineage potential of isolated cells testing their 
ability to differentiate into cells of mesodermal lineages (osteo-, condro- and adipo-
genic potentials). 
 
Aim 4: Induce hepatic differentiation by applying a two step protocol (an induction 
phase and maturation phase); confirm the acquisition of mature haepatic features by 
means of specific functional assays. 
 
Aim 5: Evaluate if induced differentiation processes alter  preterm WJ-MSCs 
immunomodulatory molecules expression.  
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3. MATERIALS AND METHODS 
 
3.1 Isolation procedure and culture conditions: 
Preterm umbilical cords were obtained following therapeutic abortions after mothers’ 
informed consent, from Reparto di Ostetricia e Ginecologia of Ospedale Civico of 
Palermo. After the harvesting procedure, the cords were stored at room temperature 
into a sterile box containing Hanks’ Balance Salt Solution (Lonza) supplemented with 
2x Antibiotic and Antimycotic solution (Sigma). The cords were normally processed 
within 12 hours from collection. 
To isolate Wharton Jelly Cells (WJCs), the immature cords were rinsed two times (10 
minutes each) into fresh HBSS and typically cutted into 1 cm pieces (3-6 pieces 
depending on the cord length), avoiding tissue drying. 
In order to expose the inner soft tissue, each piece was longitudinally and obliquely 
incised using a sterile scalpel. Furthermore, the jelly substance was gently scraped 
and each piece was placed into culture dish with Dulbecco's Modified Eagle's 
Medium (DMEM) low glucose w/glutamine (Sigma) supplemented with 10% fetal 
bovine serum (PAA), 1x non essential aminoacids (Sigma) and 1% 
antibiotic/antimycotic solution (Sigma) for cell expansion. 
The culture was maintained at 37ºC in a humidified atmosphere at 5% CO2. After 15 
days the cord pieces were removed. At ~80-90% of confluence cells were passaged 
with TrypLE Select (Gibco) at 37 ºC and centrifugation at 1100 rpm for 5 minutes. 
The viability of the isolated cells was evaluated by trypan blue exclusion. 
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3.2 Immunophenotype profiling: FACS analysis, 
immunofluorescence and immunocytochemistry staining 
In order to characterize the isolated cells, early passages of WJCs (typically P2 and 
P5) were used. 
 
Flow cytometry analysis: 
All flow cytometric acquisitions were performed on a BD FACS Aria II (Becton 
Dickinson) and data were analyzed using the software FACSDiva Version 6.1.2. 
Briefly, approximately 1 x 106 cells were used for each antibody staining. Fixation 
and permeabilization of cells were performed with the Cytofix/Cytoperm kit (BD 
Biosciences) according to manufacturer’s instructions. Cells were investigated for the 
expression of molecules whose corresponding primary antibodies are listed in Table 5 
Secondary antibodies (when required) and Isotype antibodies (BD Biosciences) were 
included as controls in each experiment. 
 
Immunofluorescence (IF): 
For immunofluorescence staining, cells were cultured in 8 well chamber slides (BD 
Biosciences). Once the cells reached confluence, each well was fixed according to 
antibody manufacturer’s instructions. After being blocked in PBS 0.5% Tween 20, 
3% bovine serum albumin (BSA) for one hour at room temperature, cells were 
incubated with the primary antibodies overnight at 4°C, rinsed with PBS, and then 
incubated with the appropriate fluorescence-conjugated secondary antibodies (Alexa 
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Fluor, Invitrogen, Carlsbad, CA) for 1 h at room temperature in the dark. Cells were 
mounted with Prolong Gold Antifade (Invitrogen), which includes diamidino-2-
phenylindole (DAPI) for the nuclear counterstaining and stored in the dark at 4°C 
until fluorescence microscope analyses. Cell imaging was done with a microscope 
(Nikon Eclipse 50i, Melville, NY) coupled with a camera (Olympus XM10, Tokio, 
Japan) and Cell F software for image acquisition (Olympus). The primary antibodies 
are listed in Table 6. 
 
Immunocytochemistry (ICC): 
For Immunocytochemistry characterization, cells were cultured in 8 well 
chamberslides (BD Biosciences). Once the cells reached confluence, each well was 
singularly stained for the expression of albumin, B7-H3, B7-1, B7-2, CK18, CK19, 
connexin 40, connexin 43, connexin 45, c-Kit., GATA-4, HLA-E, HLA-G, nestin,, 
PSG1, vWF. 
Briefly, cells were fixed with ice-cold methanol for 20 minutes, rinsed with PBS, and 
permeabilized with PBS 1x containing 0,1% Triton X-100. After a subsequent 
washing step with PBS, slides were exposed to 0.3% H2O2 in PBS and then blocked 
with blocking serum (included in Vectastain kit) according to the manufacturer's 
instructions. Next, the cells were incubated for 1.5 hrs at RT with various primary 
antibodies diluted in permeabilization buffer (The primary antibodies are listed in 
Table 6). Cells were then washed with PBS and incubated at room temperature for 30 
minutes with the appropriate secondary antibody diluted in blocking solution. 
Immunostaining was performed with ABC peroxidase staining kit (VectorLab.) and 
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Dako / AEC Substrate-Chromogen. Cells were next washed with PBS and 
counterstained with hematoxylin to identify nuclei.  
 
3.3 Adipogenic differentiation: 
Adipogenic potential was evaluated after 21-day incubation in adipogenic medium 
0.5 mM isobutylmethylxanthine (Sigma), 1 µM dexamethasone (Sigma), 10 µM 
insulin (Sigma), 200 µM indomethacin (Sigma), 10% FCS (PAA), 1x NEAA (non-
essential aminoacids) (Sigma) and 1% antibiotic-antimycotic (Sigma), using Oil red 
O staining as described previously (La Rocca et al, 2009). 
3.4 Osteogenic differentiation: 
Osteogenic differentiation was induced on monolayer cells by adding osteogenic 
soluble factors to the regular culture medium (50 µM ascorbate-2-phosphate (Sigma), 
10 mM β-glycerophosphate (Sigma), and 0.1 µM dexamethasone (Sigma).  MSCs 
cultured in normal growth medium were included as controls. After three weeks, 
calcium deposition was assessed by Alizarin red S staining as described previously 
(La Rocca et al, 2009). 
 
3.5 Chondrogenic differentiation: 
Chondrogenic induction was performed in an alginate 3D system. Before 
encapsulation, the cells were pelleted by centrifugation and resuspended at a cell 
concentration of 3 million cells/ml, in 2.4% w/v solution of sterile filtered low 
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viscosity sodium alginate (Sigma). The solution was placed in a sterile syringe and 
gently sprayed (drop by drop) in a solution containing 100mM CaCl2, causing 
gelation of the alginate as microspheres containing the cells. Groups of 4-5 
microspheres where then cultured in standard medium or chondrogenic medium 
(DMEM supplemented with 1% FBS, 6.25 mg/mL insulin, 10 ng/mL transforming 
growth factor beta 1, 50nM ascorbate-2-phosphate, 1% antibiotic–antimycotic, and 
1x NEAAs). 
After three weeks, beads were collected into 50 ml conical tubes and fixed for 4 hours 
at room temperature with 4% paraformaldehyde in 0.1 M sodium cacodylate/10mM 
calcium chloride buffer. After fixation, the specimens were overnight rinsed at 4ºC in 
50 mM BaCl2 (barium chloride) to irreversibly cross-link the alginate matrix. Then 
the beads were dehydrated with a graduated ethanol series cleared with xylene, 
embedded in paraffin and 4 µm sections were prepared. 
Histological assessment of chondrogenesis 
Before proceeding with the staining protocol, the sections were deparaffinized and 
rehydratated. Hematoxylin and Eosin staining (H&E) for morphology analysis and 
Alcyan blue staining for proteoglycan detection were performed using standard 
procedures. 
 
3.6 Hepatogenic differentiation: 
Wharton's Jelly Cells were induced to hepatic differentiation by sequential addition of 
exogenous factors to cell culture medium.  
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For the first three weeks cells were cultured in 1% FBS DMEM low glucose 
w/glutamine supplemented with FGF-4 (10 ng/mL, Miltenyi Biotech), HGF 
(20ng/mL, Miltenyi Biotech), ITS (1x, Sigma), 0,1 µM dexametasone (Sigma), 1x 
NEAA (Sigma).and 1x Antibiotic-Antimicotic solution (Sigma). For the following 
two weeks oncostatin M (10 ng/mL, Prospec) was also added to the above-mentioned 
differentiation medium.  Medium was changed three times per week and hepatogenic 
maturation was assessed at different time points (after three, four and five weeks) by 
flow cytometry, PAS staining, G6Pase assay, Indocyanine green (ICG) uptake and 
CYP3A4 assay. For each experiment samples cultured under standard conditions for 
the same timeframes were also included as controls. 
 
Glucose-6-Phosphatase (G-6-Pase) assay: 
Glucose 6- phosphatase is a key enzyme in the glucose metabolism involved in 
gluconeogenesis and glycogenolisys. In order to evaluate the activity of the enzyme, 
we used a protocol provided by Professor Etienne Sokal (University of Louvain, 
Belgium). After removing the medium, treated and control WJCs were incubated for 
20 minutes with 0.1M Tris-acetate buffer (pH 6.5) containing 2.08 mM glucose-6-
phosphate and 2.4 mM lead nitrate at 37ºC, in a fully humidified atmosphere 
containing 5% CO2. 
Active G-6-Pase hydrolyzed Glucose-6-Phosphate to free Glucose and inorganic 
Phosphate, thus inducing intracellular Pb(NO3)2 formation and precipitation. Cells 
were gently washed three times with water and then incubated for few seconds with 
ammonium sulfide 1% to convert lead nitrate into lead sulfate (brown precipitates). 
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Sulfide solution was removed and cell images were taken after an additional rinse 
with water. 
 
Cytochrome-p450-3A4 (CYP3A4):  
Xenobiotic detoxification is one of the main functions of the liver. This process is 
performed by a monooxigenase, known as CYP 450, an enzyme belonging to a 
superfamily of proteins that are involved not only acting in the first phase of 
methabolism of substances such as such as chemicals, alcohols and toxin but they 
also play an important role in the synthesis of steroid hormones. In the liver exist 
several isoforms of these enzymes, such as CYP450 3A4 and CYP450 2B6. 
Cytochrome P450 Isoform 3A4 activity was assessed by the luminescent-based assay 
P450-Glo (Promega) following manufacturer's instructions. 
Rifampicin (25 µM) and Ketoconazole (10 µM) were respectively used as CYP3A4 
inducer and inhibitor. Fresh compounds were added at 24 hours and cytochrome 
activity was measure in control and differentiated cells after. 48 hours after the 
treatments by Promega GloMax 96 Microplate Luminometer 
 
Indocyanine green (ICG) uptake: 
Cardiogreen or indocyanine green (SIGMA) is a water soluble cyanine dye that forms 
non covalent fluorescent complexes with some plasma proteins, mainly with albumin. 
Indocyanine green linked with albumin is rapidly taken up by the liver and then 
excreted unchanged into bile. Briefly, confluent cells were incubated for 15 minutes 
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at 37ºC with a solution of ICG in culture medium (1mg/mL, Sigma). After three 
washes with PBS, cells were microscopically observed and imaged. 
 
Periodic Acid-Schiff staining: 
Periodic Acid Schiff staining (PAS-staining) is a staining method that allow the 
detection of polysaccharides such as glycogen and mucopolysaccharides. The 
periodic acid oxides the diol functional groups these sugars, creating aldehydes. The 
aldehydes subsequentely react with Schiff reagent generating a purple-magenta 
colour. WJCs grown in 8-well chamber slides were fixed in 4% paraformaldehyde (in 
ethanol) for 1 minute at room temperature and glucose metabolism was analyzed by 
glycogen Periodic Acid-Schiff (PAS) (Sigma Aldrich) according to manufacturer’s 
instructions prior to microscopic examination and imaging. 
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TABLE 5: List of antibodies used for flow cytometry analyses 
 
Antigen Clone Conjugated Dilution Manufacturer 
Albumin 188835 uncon-jugated 1:400 R&D Systems 
AFP 189506 unconjugated 1:800 Cedarlane 
CD10 HI10a APC 1:20 Becton Dickinson 
CD11b 
ICRF44 
(also 
known as 
44) PE CY7 1:20 Becton Dickinson 
CD13 WM15 APC 1:20 Becton Dickinson 
CD14 MφP9 APC CY7 1:20 Becton Dickinson 
CD29 mar-04 APC 1:20 Becton Dickinson 
CD31 WM59 FITC 1:20 Becton Dickinson 
CD34 581 FITC 1:20 Becton Dickinson 
CD44 
G44-26 
(also known 
as C26) APC 1:20 Becton Dickinson 
CD45 2D1 PerCP 1:20 Becton Dickinson 
CD54 HA58 APC 1:20 Becton Dickinson 
CD68 Y1/82A PE 1:20 Becton Dickinson 
CD71 M-A712 APC 1:20 Becton Dickinson 
CD73 AD2 APC 1:220 Miltenyi Biotec GmbH, Bergisch Gladbach, DE 
CD90 (Thy-1) 5 E10 FITC 1:400 Becton Dickinson 
CD105 SN6 FITC 1:20 Abcam, Cambridge, MA 
CD106 51-10C9 APC 1:20 Becton Dickinson 
CD117 YB5.B8 PE 1:20 Becton Dickinson 
CD166 3A6 PE 1:20 Becton Dickinson 
CD276 FM276 APC 1:220 Miltenyi Biotec GmbH 
CD309 89106 APC 1:20 Becton Dickinson 
CK18 C-04 FITC 1:400 Abcam, Cambridge, MA 
CK19 RCK108 PE 1:400 Santa Cruz Biotechnology, Santa Cruz, CA 
EpCAM EBA-1 FITC 1:20 Becton Dickinson 
E-Cadherin 36 FITC 1/2000 Becton Dickinson 
HLA ABC W6/32 FITC 1/6000 Abcam Cambridge, MA 
HLA DR 
L243 (G46-
6) PerCP 1:20 Becton Dickinson 
HLA-G 87G PerCP 1:20 eBioscience Inc., San Diego, CA 
HLA-E 
3D12HLA-
E APC 1:20 eBioscience 
IgG1 G18-145 FITC 1:20 Becton Dickinson Biosciences, San Jose, CA 
IgG2 PC10 PE 1:20 Becton Dickinson 
Oval cell  OV-6 unconjugated 1/2000 Santa Cruz Biotechnology 
Vimentin VI-RE/1 PE 1:20 Abcam, Cambridge, MA 
STRO-1 MM-30 APC 1:20 Biolegend, San Diego, CA  
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TABLE 6: List of antibodies used for Immunocytochemistry and 
Immunoflourescence assays. 
Antigen Host Manufacturer Dilution 
(IF) 
Dilution (ICC) 
Albumin Mouse Santa Cruz N/A 1:100 
B7-1 Mouse Santa Cruz N/A 1:50 
B7-2 Mouse Santa Cruz N/A 1:800 
B7-H3 Rabbit Santa Cruz 1:50 1:300 
Connexin 40 Rabbit Santa Cruz 1:50 1:100 
Connexin 43 Rabbit Santa Cruz 1:50 1:100 
Connexin 45 Rabbit Santa Cruz 1:50 1:100 
Cytokeratin 8 Mouse Sigma N/A 1:200 
Cytokeratin 18 Mouse Sigma N/A 1:800 
c-Kit Rabbit Epitomics 1:20 1:50 
GATA-4 Rabbit Santa Cruz? 1:100 1:100 
Nestin Mouse Santa Cruz 1:100 1:100 
HLA-E Mouse Santa Cruz N/A 1:100 
HLA-G Mouse Santa Cruz N/A 1:100 
PSG-1 Mouse Santa Cruz N/A 1:100 
Von Willebrand 
factor 
Mouse Santa Cruz N/A 1:100 
 
 54
4. RESULTS 
 
4.1 ISOLATION AND EXPANSION OF MESENCHYMAL CELLS 
FROM PRETERM UMBILICAL CORDS  
For the present study, eight specimens were used, which correspond to a gestational 
age ranging between 15 to 22 weeks.  
The isolation protocol applied resulted in the derivation of homogeneous populations 
of cells with fibroblastoid morphology with plastic adherence. Only for one of the 
eight umbilical cords used we were not able to derive a cellular population, due to a 
traumatic abortion procedure. Otherwise, no other subjective differences between the 
samples did influence the isolation procedure or the subsequent culturing phase. A 
detailed list of the preterm cords used for this study is summarized in Table 7.  
Fibroblast-like cells exiting from tissue pieces were visible after about 4-5 days 
following tissue processing. The morphology of such cells strikingly resembled that 
of mesenchymal stem cells of different tissue origin. As shown in Figure 9, preterm 
WJ-MSCs exhibit a large nucleus containing a variable number of nucleoli and a cell 
body that is larger compared with term WJ-MSCs. As observed earlier for full-term 
WJ-MSCs, also for preterm ones, at confluence the cells changed their shape, 
assuming a tapered and elongated morphology with arrangement in strictly packed 
parallel rows.  
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Primary cell cultures were rapidly expanded up to nine-ten passages, without losing 
their proliferative potential. Adherent cells at passage two and five were chosen for 
the subsequent characterization by flow cytometry, ICC and IF.  
 
SAMPLE CODE GESTATIONAL 
AGE 
FOETAL 
PATHOLOGY 
CELL PASSAGE 
MES 11_13 21 weeks Trisomy 21 p9 
MES 11_14 21 weeks Multiple Pathologies  
(Cystic Hygroma..) 
p10 
MES 11_15 16 weeks Trisomy 21 N/A 
MES 11_16 15 weeks Trisomy 21 p9 
MES 11_17 20 weeks Spina Bifida p10 
MES 12_01 21,5 weeks Spina Bifida p9 
MES 12_02 22 weeks Bilateral 
ventriculomegaly p7 
MES 12_03 16 weeks Cardiac insufficiency p7 
TABLE 7: Pretterm umbilical cords  used for the present study. 
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Figure 9: Phase contrast images showing morphological features of preterm cord 
derived WJ-MSCs (violet) compared to WJ-MSCs isolated from term umbilical cords 
(red). 
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4.2 PHENOTYPICAL CHARACTERIZATION OF 
UNDIFFERENTIATED WJ-DERIVED CELLS FROM PRETERM 
UMBILICAL CORDS BY FLOW CYTOMETRY, 
IMMUNOFLUORESCENCE AND IMMUNOCYTOCHEMISTRY 
ANALYSES. 
 
Culture-expanded cells derived from preterm umbilical cords (p2 and p5), were 
analyzed by flow cytometry, immunofluorescence and immunocytochemestry, 
showing a phenotype that is overall similar to that of MSCs derived from other 
tissues.  
To date, an exclusive set of antigens that could be used to uniquely identify 
mesenchymal stem cell population is still lacking, and MSCs are described as being 
positive for the expression of several mesodermal antigens and negative for the 
expression and hematopoietic and endothelial markers. 
In order to provide an ample characterization of preterm MSCs antigenic profile, we 
defined a panel of 45 antibodies used to identify antigens that, based on their 
expression in different mature tissues derived from the three germ layers, or their 
functions, were grouped into five categories: 
- Mesodermal antigens (11) 
- Hematopoietic markers (4) 
- Endothelial antigens (3) 
- Immunomodulatory antigens (11) 
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- Hepato-specific antigens (6) 
- Other antigens (10) 
Flow cytometry immunophenotyping showed that, regardless the foetal pathology 
associated with the umbilical cord and independently from the gestational age of the 
foetus, all primary cell cultures were markedly positive for mesodermal antigens 
(CD29, CD44, CD73, CD90, CD105, CD71, CD106, CD13, CD10, CD166, CD54 , 
Fig. 10-A) and negative (or weakly positive) for typical hematopoietic (CD45, CD34, 
CD14, CD68, CD309, Fig. 10-B) and endothelial markers (CD31 and Von 
Willebrand factor, the last evaluated by Immunocytochemistry,  Fig. 10-C). 
Considering the results altogether, more than 90% of the overall cell population at 
passage five expressed CD90, CD29, CD13, CD10, CD73 and CD24 antigens, 
whilethe expression of CD105 was more sample-dependent, with marked individual 
differences. This is not surprising since even if CD105 is one of the most commonly 
reported markers to be expressed in MSCs, a variable or low expression of this 
molecule has already been reported by others [reviewed in 179] and this variability 
may also be related to the lower gestational age of our samples. 
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Figure 10: Preterm WJ-MSCs do express mesodermal antigens and lack both hematopoietic 
and endothelial ones. Flow cytometry data (A) showed that for most of the markers 
associated to the MSCs phenotype, WJ-MSCs were positive, while lacking hematopoietic 
markers (B). ICC was used to demonstrate the absence of vWF, a marker of mature 
endothelial cells (C). Magnification: 20 x.  
 60
Wharton's jelly MSCs are known to prominently express also a number of 
immunomodulatory molecules, which were correlated to the low immunogenicity of 
these cells both in vitro and in vivo. In particular, undifferentiated WJ-MSCs were 
characterized for the expression of markers such as class I and class II MHC and the 
expression of the costimulatory molecules CD80 (B7-1) and CD86 (B7-2), which is 
required for the development of T cell responses. The definition of  an 
immunomodulatory profile is very important because it gives important indications, 
that could be very helpful to define the properties of these cells as possible candidates 
for in vivo cellular therapy applications. 
As shown in Figure 11, all of the investigated preterm WJ-MSCs populations did 
express type I MHC (HLA-ABC) at high levels, while lacking expression of type II 
MHC (HLA-DR). In addition, molecules belonging to the type Ib MHC (HLA-E and 
HLA-G), were also demonstrated to be expressed in our cells, albeit at lower levels 
with respect to classical type I MHC. In addition, no expression of CD80 or CD86 
was detectable in any of our cell lines, thus constituting a favourable phenotype with 
regard to lymphocyte stimulation ability. More interestingly, preterm WJ-MSCs did 
express high levels of CD276 (B7-H3), which is another member of the B7 family. 
The function of B7-H3 is still unknown but it has been postulated that it may exert 
immunoprotective and tolerogenic functions, attenuating peripheral immune 
responses through co-inhibition. 
The expression of high levels of class I MHC is very important because these 
molecules can act “protecting” mesenchymal stem cells from certain NK cell 
mechanisms of deletion (e.g. NK cells kill tumor cells that have downregulated class 
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I) [180]. The absence of HLA-DR expression (<1%) indicates a reduced 
immunogenicity through the control of alloantigen expression [181], giving MSCs the 
possibility to escape recognition by alloreactive CD4+ T cells. In addition, preterm 
WJ-MSC do not express CD80 and CD86, two of the co-stimulatory molecules 
required for effector T cell induction [182]. The absence of co-stimulatory molecules 
is a significant observation. It implies that any residual engagement of the T cell 
receptor on Th cells would result in anergy and contribute to tolerance rather than 
allogeneic responses. 
As stated above, we investigated the expression of two non-classical type I HLAs that 
are HLA-E and HLA-G, evaluated by flow cytometry and ICC. The results obtained 
indicated expression of HLA-E (the average value at passage 5, evaluated by flow 
cytometry, is 15%, in accordance to the ICC results that are here not shown) and low 
levels of HLA-G, which varied with respect to the different cell lines in a subjective 
fashion (Fig. 11A). The expression of HLA-E and HLA-G has been linked to the 
immunomodulatory ability of MSCs, and it constitutes part of the immunomodulatory 
machinery of the embryo and placenta to modulate the immune response of the 
mother towards the semi-allogeneic fetus. 
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Figure 11: Immunomodulatory molecules expressed by preterm WJ-MSCs were assessed by 
flow cytometry (A) and immunofluorescence (B). 
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Single labeling experiments have also shown the presence of tissue-specific markers 
in undifferentiated preterm WJ-MSCs such as Nestin (Figure 12-B), GATA-4 and c-
Kit (shown respectively in Figure 12 A and 12C,  connexins (Connexin 40, Connexin 
43, Connexin 45 Figure 13 A-C ), and other antigens known to be expressed in 
“hepatic progenitor cells and mature hepatocytes”. 
Nestin is an intermediate filament first characterized in neuroepithelial stem cells 
whose expression was subsequently demonstrated also in progenitor cells of different 
origins such as hepatic progenitor cells, pancreatic endocrine progenitor cells and also 
in embryonic-derived progenitor cells. Based on all these observation, it was 
postulated that it represent a marker expressed in mutipotent stem cells [183]. 
Connexins are transmembrane proteins extensively expressed in cardiac tissue at the 
level of gap junctions. In particular, Connexin 40 and 45 are involved in cardiac 
morphogenesis and electrical impulse transmission [33], whereas Connexin 43 is also 
expressed in the bone marrow, thymus, spleen, and other lymphoid tissues [32,184]. 
GATA-4 is a zinc finger transcription factor (TF) expressed in endoderm derived 
tissues (such as liver and lung) and also in heart [185]. As demonstrated by ICC and 
IF (Fig.12 A), this TF is localized in the cytoplasm and perinuclearly indicating an 
inactive state in undifferentiated cells. 
C-Kit (also called CD117) is a proto-oncogene, which encodes for the receptor for 
Stem Cell Factor (a growth factor). It is expressed by many cellular types such as 
hematopoietic stem cells, basal cells of the skin, melanocytes and germ cells. Its 
expression was also demonstrated in WJ-MSCs isolated from term umbilical cords, 
 64
whereas bone marrow derived MSCs lack the expression of this marker (reviewed in 
Anzalone et al, 2010 [186]. 
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Figure 12: Expression of tissue-specific markers in WJ-MSCs: GATA-4 and Nestin 
(A,B) are amply expressed by WJ-MSCs, while c-Kit is present in a significative 
fraction of cells (C), as shown also by flow cytometry data at passages 2 and 5 (D). 
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Figure 13: Undifferentiated preterm WJ-MSCs express high levels of connexins 40, 
43 and 45 (A-C). These transmembrane proteins are typically expresses by 
cardiomiocytes and are part of gap-junction channels (D). 
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Moreover, we investigated the expression of hepato-specific markers by flow 
cytometry and ICC. WJ-MSCs express high levels of alpha-fetoprotein, albumin and 
cytokeratins, namely CK8, CK18 and CK19 (Figure 14 A-D). The expression of 
hepatic markers by umbilical cord cells isolated by Wharton's jelly of mature 
umbilical cords was also reported by us and others [73, 80] liver specific antigen 
expression was also published by other groups investigating phenotypic expression 
and multilineage differentiation capabilities of mesenchymal stem cells isolated from 
different origins such as adipose-derived MSCs [156]. 
All of these markers (together with c-Kit receptor) were found to be co-expressed by 
oval cells (figure 14 E), bipotential hepatic stem cells that play a major role in liver 
regeneration after injuries, giving rise to hepatocytes (CK8+, CK18+, albumin+, 
AFP+) and duct cells (CK19), thus restoring liver mass.  
The observed expression of liver-specific markers suggests that preterm WJ-MSCs 
may have an intrinsic ability to differentiate into hepatocyte-like cells. 
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Figure 14: Undifferentiated WJ-MSCs express markers of bipotent hepatic stem cells named 
oval cells (E) such as CK8, CK18, CK19, albumin and α-fetoprotein (AFP), as assessed by 
cytofluorimetric (A) and immunocytochemistry analyses (B-D).  
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Table 8: Global results of the semiquantitative evaluation of multiple markers in WJ-MSCs, 
assessed by ICC, and cross confirmed by flow cytometry and immunofluorescence analyses. 
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4.3 IN VITRO DIFFERENTIATION TOWARDS THE 
MESODERMAL LINEAGES: ADIPOGENIC, OSTEOGENIC AND 
CHONDROGENIC DIFFERENTIATION 
To confirm the stemness of the isolated cells, we performed the classical tri-lineage 
differentiation experiments, to test their ability to differentiate towards adipocyte, 
chondrocyte and osteocyte lineages, by applying standard protocols. 
 
4.3.1 ADIPOGENIC DIFFERENTIATION 
Adipocyte differentiation begins with an accumulation of small lipid-rich vacuoles 
into the cytoplasm of MSCs starting to be committed to pre-adipocytes. 
Subsequently, these cells turn into mature adipocytes containing larger fat droplets 
derived from small lipid vesicles fusion events. Adipogenic induction has been 
performed in monolayer cultures using a previously described protocol based on the 
use of multiple specific inducers. 
After three weeks of induction, adipogenic differentiation occurred in our cells as 
demonstrated by the visible accumulation of lipid droplets in the cytoplasm of treated 
cells, with respect to control ones, highlighted by the use of Oil-red-O dye. (Figure 
15) 
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Figure 15: Microscopic demonstration of adipogenic differentiation of WJ-MSCs. 
Differentiated cells accumulated neutral lipid vacuoles in the cytoplasm, which were stained 
by Oil red O dye (lower panels). Control cells (upper panels) did not show any staining. 
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4.3.2 OSTEOGENIC DIFFERENTIATION 
Bone is a specialized connective tissue consisting of cells surrounded by an 
extracellular matrix (ECM) containing both inorganic salts (mainly hydroxyapatite 
and calcium carbonate) and proteins (collagen fibers and non-collagen proteins). 
Osteoblasts are mesenchymal-derived cells specialized for the synthesis and the 
secretion of both the inorganic and organic constituents of the ECM. WJ-MSCs were 
subjected to osteogenic differentiation for three weeks in a specific medium, and then 
the deposition of a mineralized extracellular matrix was assessed by Alizarin Red 
staining. This dye specifically marks extracellular calcium deposits highlighting 
osteogenesis. As visible in panels in Figure 16, differentiated cells showed high 
levels of extracellular calcium deposits indicating a successful osteogenic 
differentiation, with respect to controls cultured for three weeks in standard growth 
medium. 
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Figure 16: Microscopic demonstration of osteogenic differentiation of WJ-MSCs. 
Differentiated cells deposited a calcium-enriched extracellular matrix, which was stained by 
Alizarin red S dye (lower panels). Control cells (upper panels) did faint staining. 
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4.3.3 CONDROGENIC DIFFERENTIATION 
MSCs were also described to be able to differentiate into chondrocytes. 
Chondrogenic differentiation was achieved under standard differentiation conditions 
in a three-dimensional system (alginate beads) mimicking the physiological milieu.  
After 21 days differentiation, cells were uniformly distributed into the matrix and 
MSCs changed their shape, assuming a rounded morphology with large nuclei stained 
with nuclear fast red, in both control and treated conditions (Figure 17, arrows). 
Treated beads showed an increased level of glycosaminoglycans (GAG) into the bulk 
of extracellular matrix, as demonstrated by the intense blue staining obtained via 
Alcian blue dye. This was not visible into the parallel control beads (Figure 17).  
This indicates that in vitro the cells acquired a matrix synthesis activity of specific 
cartilage molecules, such as those expressed by chondroblasts during development. 
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Figure 17: Microscopic demonstration of chondrogenic differentiation of WJ-MSCs. 
Differentiated cells secreted glycosamminoglycans in the extracellular spaces, which were 
stained by Alcian Blue dye (lower panel). Control cells (upper panel) did not show any 
staining. Arrows indicate cell nuclei counterstained with nuclear fast red. 
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4.4 IN VITRO DIFFERENTIATION POTENTIAL OF WJ-MSCs 
TOWARDS HEPATIC LINEAGE 
Hepatic differentiation was achieved by applying a two step protocol developed by 
my group [Lo Iacono et al, manuscript in preparation] consisting of a “pre-inductive 
step and a maturation step” that mimics in vitro, in a time dependent manner, some of 
the inductive events that take place during the foetal liver morphogenesis. 
During the pre-inductive step 80% confluent cells, grown on plastic supports, were 
cultured for three weeks in a medium supplemented with 1% FCS, 
antibiotic/antimycotic, non essential aminoacids, HGF (hepatocyte growth factor), 
FGF-4 (fibroblast growth factor-4), dexamethasone, and insulin-transferrin-selenite 
(ITS). Subsequently, cells were grown in a maturation medium containing oncostatin 
M (OSM) in addition to all the over mentioned factors. FGF-4, HGF and oncostatin 
M are cytokines that exert a crucial function in liver morphogenesis, being involved 
during different developmental stages and also playing diverse roles in hepatic 
differentiation: the first two early activating a cascade of events that lead to hepatic 
cell differentiation whereas OSM is fundamental for the maturation and the 
maintenance of hepatic differentiated phenotype. 
After 3, 4, and 5 weeks cellular modifications, both at the morphological and 
functional level, were investigated respectively by microscopy, ICC and functional 
assays. 
After three weeks of induction, cells exposed to hepatogenic differentiation medium 
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showed a morphological transition, from a typical fibroblastic-like shape to a 
polygonal-like morphology that closely resembles that of hepatocytes, suggesting an 
active maturation process toward a hepatocyte-like phenotype (an example is 
indicated in red colour in Figure 18). Moreover, cytoplasm granules were observed 
in hepatic differentiating cell as indicated by black arrows in Figure 18. 
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Figure 18: Phase contrast micrographs showing the morphological transition of WJ-MSCs 
subjected to hepatic differentiation. While control cells (upper panel) retain the fibroblastoid 
morphology during culture, hepatocyte-like cells assume a polygonal shape (highlighted by 
red arrow) and show the presence of granulation in the cytoplasm (black arrows) 
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4.4.1 PERIODIC ACID SCHIFF (PAS) STAINING 
 
After three weeks of culture in standard growth medium, PAS staining revealed low 
levels of glycogen deposits in undifferentiated cells, whose expression was 
maintained constant up to the 5th week (Figure 19, upper panels). The presence of 
glycogen in the cytoplasm of Wharton’s jelly native mesenchymal stem cells, 
together with cytofluorimetric and immunocytochemistry data revealing the 
expression of alpha fetoprotein, albumin, and cytokeratins 8 and 18, indicate that 
among the WJ-MSCs population there are some cells that express basal levels of 
hepatic markers, thus suggesting an intrinsic predisposition to differentiate into 
hepatic-like cells. 
Hepatic induction after three, four and five differentiation weeks resulted in an 
evident increase of glycogen deposits, clearly indicating an enhancement of the 
expression and the activity of the enzyme Glycogen synthase (Figure 19, lower 
panels). 
We next wanted to evaluate whether the evidence of mesenchymal−hepatic transition, 
revealed by phenotypic changes in response to differentiation stimuli, was associated 
with the acquisition of other mature hepatic function. 
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Figure 19: Microscopic demonstration of glycogen accumulation by PAS staining. Control 
cells (upper panels) grown in standard medium, show moderate staining, while differentiated 
cells (lower panels) show more intense staining. 
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4.4.2 CYTOCHROME P450 (CYP3A4) ACTIVITY QUANTIFICATION 
Liver represents the major site of xenobiotic metabolism, a process consisting of 
multiple biochemical transformations aimed to prevent the accumulation of toxic 
substances globally indicated as “xenobiotics” (e.g. pharmacological compounds and 
toxins) transforming them into inactive metabolites. Hepatocytes contain a wide 
range of enzymes to process xenobiotics, some of which belong to the cytochromes 
P450 family: monooxigenases that catalyze the first phase of the metabolism of many 
xenobiotics. 
Isoform 3A4 of cytochrome p450 (CYP 3A4) represents the most abundant 
cytochrome of liver and its activity is considered to be one of the most important 
parameters used to demonstrate the acquisition of hepatic maturity by precursor cells. 
We therefore decided to measure CYP3A4 activity in control and treated WJ-MSCs 
in response to Rifampicin (its specific inducer), with or without the addiction of its 
specific inhibitor ketoconazole, by using a luminometric assay. 
The obtained results, shown in Figure 20, indicate no major differences in 
cytochrome activity in both control and treated cells after four weeks of hepatic 
induction. On the contrary, cells cultured in hepatic induction medium for five weeks 
exhibited an enzymatic activity induced by Rifampicin that is markedly higher than 
the one measured in correspondent control cells. Moreover, the activity of the enzyme 
decreased following the incubation with Rifampicin and Ketoconazole, thus 
confirming the specificity of CYP3A4 activity measurement. Homogeneous results 
were obtained at five weeks in all considered samples. These data, albeit not reaching 
the statistical significance, strongly suggest that WJ-MSCs acquire the ability to 
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metabolize xenobiotics in an inducible manner following the applied differentiative 
stimulus. 
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Figure 20: Evaluation of CYP3A4 induction following rifampicin challenge in 
undifferentiated and differentiated WJ-MSCs at different time points. The activity of the 
enzyme was specifically inhibited by the addition of ketoconazole to culture medium. 
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4.4.3 GLUCOSE-6-PHOSPHATASE (G-6-Pase) ASSAY 
We also investigated glucose-6-phosphatase activity in both undifferentiated and 
hepatocyte-like cells. G-6-Pase is one of main hepatic enzymes involved in glucose 
metabolism. As shown in Figure 21, at all considered time points, hepatocyte-like 
cells exposed to the enzyme substrate were able to form lead sulfate precipitates, with 
their characteristic black-brown colour, indicating an intense G-6-Pase activity 
compared to that observed in control cells at the same time points. 
 
4.4.4 INDOCYANINE GREEN (ICG) UPTAKE 
Another parameter which may be evaluated to demonstrate the acquisition of a 
hepatocyte-like phenotype is the uptake of indocyanine green, also referred to as 
cardiogreen. Cardiogreen is an organic anion that is selectively taken up by 
hepatocytes and that is able to bind plasma proteins, and particularly albumin. It is 
clinically used because its uptake, storage, and excretion by the liver give useful 
indication of hepatic function. 
As visible in Figure 22, control cells did not show any green colour, whereas 
hepatocyte-like cells exhibited intense green cytoplasmatic staining indicating dye 
internalization. 
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Figure 21: Microscopic demonstration of G6Pase Activity, assessed by a colorimetric enzymatic 
assay, showing production of intracellular lead nitrate precipitates at higher levels in differentiated 
cells (right panels) with respect to undifferentiated ones (left panels). magnification: 20x. 
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Figure 22: Microscopic demonstration of ICG uptake by differentiated cells (right ) with respect to 
control ones (left). 
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4.4.5 IMMUNOMODULATORY ANTIGENS EXPRESSION IN 
UNDIFFERENTIATED AND DIFFERENTIATED WJ-MSCs 
As previously discussed, one of the most attractive features of mesenchymal stem 
cells is their hypoimmunogenicity, since these cells may inhibit allogeneic 
lymphocytes proliferation in vitro, and are also tolerogenic when infused in vivo in 
immunocompetent hosts. This has been linked to the peculiar phenotype of these 
cells, which for example lack expression of major histocompatibility complex class II 
molecules, and which are also able to produce secreted molecules known to interfere 
with the immune function at various levels. Recent literature data pointed out the 
occurrence of immunomodulatory molecules also in the differentiated progeny of 
stem cells, in particular for WJ-MSCs and hAECs. Since, as shown above, we have 
demonstrated in our cells the expression of other interesting imunomodulatory 
molecules such as B7-H3, also involved into immune tolerance, we wanted to further 
evaluate whether preterm WJ-MSCs may also maintain the expression of 
immunomodulatory molecules. 
Therefore, by flow cytometry analyses on undifferentiated and differentiated preterm 
WJ-MSCs, subjected to adipo- osteo- and hepato- differentiation inductions, we 
assessed the levels of the immunomodulatory molecules and the variations with 
respect to the naive cells. 
As shown in Figure 23, and confirming the results recently obtained with WJ-MSCs 
derived from mature cords, preterm WJ-MSCs subjected to both osteogenic or 
adipogenic differentiation did maintain the expression of B7-H3 and HLA-E at levels 
comparable to the control cells. More interestingly, also cells subjected to the hepatic 
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differentiation (Figure 24) showed the maintenance of the immunomodulatory 
molecules expression, thus suggesting the possibility that hepatocyte-like cells may 
also be better tolerated when infused in vivo. 
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Figure 23: Immunomodulatory molecules expression following adipogenic and 
osteogenic differentiation protocols in treated (adipo and osteo) and control cells (nt).
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Figure 24: Immunomodulatory molecule expression following hepatogenic 
differentiation in treated (Hep) and control cells (nt) 
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5. DISCUSSION 
Stem cells research is a field that over the last three decades has been characterized 
by a rapid and tremendous expansion representing, without any doubt, the future of 
biomedical research and applicative medicine which, hopefully one day, will make 
stem cell administration one of the possible therapeutic treatments to cure several 
diseases and pathological conditions. 
The large collection of scientific data obtained so far from in vivo models, and above 
all, the promising results collected from the increasing number of clinical trials that, 
in particular, make use of adult stem cells such as bone marrow derived mesenchymal 
stem cells and haematopoietic stem cells, have created a general optimism about 
future stem cell applications. 
Contextually, stem cells have been demonstrated to be a useful tool to screen in vitro 
the toxicity of pharmaceutical compounds, as well as an interesting model to study 
some of the mechanisms underlying cancerogenesis and tumour progression (cancer 
stem cells). Hopefully the comprehension of these complex phenomena, in the future, 
will allow the formulation of new drugs that will be more effective than the ones 
currently used to treat different types of cancer.  
Regardless all these evidences, there are still a huge amount of questions that have to 
be answered, and also many problems associated with the use of stem cells have to be 
addressed. 
There are several issues associated with each stem cell category including ethical 
concerns (embryonic/fetal stem cells), the possibility to give rise to teratomas 
(embryonic stem cells) and in some cases the invasiveness of stem cell collecting 
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procedure (bone marrow mesenchymal stem cells) as well as some limitations of stem 
cell intrinsic properties such as the ex vivo expansion and differentiation potentials 
(adult stem cells). 
During the last decade the interest of the scientific community has been focused on a 
particular group of tissues indicated as “perinatal tissues” which include foetal 
annexes such as placenta, amniotic membranes and umbilical cord. 
Several reports have demonstrated many advantages regarding the use of these cells 
over embryonic and adult stem cells, suggesting that perinatal stem cells may 
represent the most promising stem cell source for regenerative medicine and for the 
treatment of various diseases. 
During the last years my research group has been studying mesenchymal stem cells 
isolated from Wharton’s jelly, the umbilical cord mucous connective tissue 
containing a primitive mesenchymal stromal stem cell compartment. The results 
obtained so far demonstrated that WJ-MSCs in vitro display a high self renewal, 
clonogenicity, a stable karyotype and, in response to specific stimuli, they can be 
differentiated into adipo-, chondro- and osteo-like cells. 
Moreover, WJ-MSCs can be induced to undego hepatogenic differentiation applying 
a two step protocol developed by my group that mimics the main differentiation 
events which take play in vitro. Interestingly, the obtained hepatocyte-like cells were 
also demonstrated to retain the expression of some immune-modulatory molecules 
involved in tolerance mechanism, previously characterized in naïve WJ-MSCs [80]. 
Another advantage over BM-MSCs is that WJ-MSCs expansion potential is higher 
and these cells in vitro can also proliferate more rapidly than bone marrow-derived 
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ones. In addition, the number of progenitor cells present in umbilical cord matrix is 
the highest of the human body (1/133-1/1609 clonogenic cells in WJ versus 1/10000-
36000 of BMSCs, 8.2±0.6 per 108nucleated cells in UCB or the foetal circulation and 
less than 1/ 106 mononuclear cells in adult whole bone marrow (Reviewed in [187]). 
Recent reports suggested that stem cells potency diminishes as function of the age of 
donor tissue, with ESCs showing the higher potency and adult stem cells being more 
restricted. Therefore, WJ-MSCs are in a developmental position which may ensure 
their differentiation into multiple adult populations, without the limits listed for 
ESCs. Following this concept, we hypothesized that Wharton’s jelly mesenchymal 
stem cells isolated from umbilical cords at an earlier developmental stages (such as 
preterm umbilical cords made available from therapeutical abortions), may feature a 
higher degree of stemness in terms of differentiation potential. 
To date there is lack of literature data describing the phenotypic profile of these cells, 
or their differentiation potency. The only preterm umbilical cord available data were 
included in a patent application filed some years ago [189], containing the description 
of an enzymatic method, based on collagenase type I digestion, that allowed 
mesenchymal stem cells isolation from first trimester umbilical cords. The patent 
application includes a partial description of some of the cellular surface antigens 
characterized on these cells by immunocytochemistry, as well as the displayed 
osteogenic and adipogenic differentiation potentials. The partial nature of the 
information contained in this application, together with the need to better characterize 
the potential of these cells for regenerative medicine applications, further justified 
this research project. 
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The main objectives of my research project were to phenotypically characterize 
mesenchymal stem cells isolated from preterm umbilical cords and to investigate 
their differentiation potential in order to evaluate if these cells could also represent an 
additional stem cell source that could find a future application in regenerative 
medicine. Moreover, an additional task was represented by the characterization of the 
immunomodulatory molecules expressed by these cells both in the undifferentiated 
and differentiated states. 
Cells isolated by plastic adherence from preterm umbilical cords showed a fibroblast-
like morphology, with a cell body that is more expanded if compared with the 
corresponding cells isolated from term umbilical cords. Phenotypical analyses 
(including flow cytometry, ICC and IF) demonstrated collectively that these cells 
were mainly adherent to the MSCs phenotype, with the relevant expression of key 
molecules (such as CD117, nestin, albumin, alpha-fetoprotein, connexins) which 
might indicate their differentiative ability towards ectoderm-, mesoderm- or 
endoderm-derived mature tissues. In addition, this initial phase also allowed to 
demonstrate that preterm WJ-MSCs do express many immune-related antigens, 
which were also characterized recently in the mature counterpart, such as HLA-E, 
CD276, and at some extent, also HLA-G. This, together with the expected negativity 
for type II MHC and positivity to classical type I MHC, strongly suggests a 
hypoimmunogenic and immunomodulatory phenotype for these cells. 
WJ-MSCs immunomodulatory features (as for T-cell anergy induction) can be 
explained by both cell-cell interactions and bioactive molecule secretion; moreover, it 
has been demonstrated that the expression of surface antigens such as HLA-G and 
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HLA-E (type Ib MHC molecules) as well as the presence of CD276 are responsible 
for tolerogenic features of WJ-MSCs. In particular, the protein encoded by CD276 
gene (demonstrated to be highly expressed in both preterm and term WJ-MSCs) is 
named B7-H3: it belongs to the immunoglobulin superfamily and it is thought to 
participate to the regulation of T-cell-mediated immune responses. 
In order to demonstrate the adherence to the mesenchymal stem cells features, we 
then evaluated the differentiation of these cells toward mesodermal lineages 
(adipocytes, condrocytes and osteoblasts) in response to specific culture conditions. 
As expected, preterm WJ-cells gave rise to adipo-, osteo- and chondro-like cells , thus 
providing a formal proof of their stemness.  
Then, we addressed the question of whether preterm WJ-MSCs could undergo 
hepatogenic differentiation as previously demonstrated for mesenchymal stem cells 
isolated from the matrix of mature umbilical cords. 
Hepatic differentiation of stem cells is currently a “hot topic” because of the need of 
alternative approaches to treat end stage liver diseases. In fact, despite liver 
transplantation is the most effective treatment for acute or chronic liver failure 
resulting from a variety of causes, to date the number of donor organs available for 
transplantation is not sufficient if compared with the number of patients in the 
waiting lists, most of which die waiting for a transplantation procedure. For this 
reason many research groups have moved to evaluate alternative therapeutical 
strategies that at least could act as bridge therapies for patients waiting liver 
transplantation. 
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Achievement of hepatic differentiation was evaluated by morphological and 
functional analyses, after applying a two step differentiation protocol that mimics 
some of the main events that take place during hepatogenesis in vivo. 
The acquisition of mature hepatic features was confirmed by PAS staining (that 
showed low glycogen levels in naive cells, which accumulation was significantly 
increased after differentiation events) and hepatocyte specific functional assays such 
as Cytocrome p 450 (isoform CYP3A4) activity, Glucose 6-Phospatase assays as well 
as Indocyanine uptake. Overall, our data showed that cells differentiated from 
preterm WJ-MSCs were able to respond to CYP3A4 inducers, with an increase in the 
activity of the enzyme which was also abolished using a specific inhibitor. Moreover, 
glucose-6-phosphatase activity was demonstrated in differentiated cells with respect 
to control ones, so as for the indocyanine green uptake. These functional assays 
constitute reliable proofs of the acquisition of a mature hepatocyte-like phenotype by 
these cells. 
Finally, we wanted to verify if preterm WJ-MSCs induced to differentiate towards 
mesodermal and endodermal cells expressed the immune-modulatory antigens 
involved in tolerance mechanism, previously demonstrated in untreated cells. Our 
results indicated that the expression of immunomodulatory antigens remained almost 
unvaried in all the considered differentiated cell populations. 
Overall, the data obtained during the PhD project provided novel and useful 
information on the features of preterm WJ-MSCs, which can be reliably isolated from 
abortion foetuses, and present a number of key features for their use in regenerative 
medicine approaches. In particular, these cells appear to express the same 
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immunomodulatory molecules which have been characterized in the mature 
counterpart (i.e. isolated from term cords) and which may provide an effective 
advantage when transplantation in an immunocompetent host is attempted. In 
addition, these features are maintained also following the application of several 
differentiation stimuli. This is an important feature since multiple literature data 
suggest that the engraftment potential of pre-differentiated cells may be superior to 
that of undifferentiated ones in certain settings. Therefore, it may be imagined that 
hepatocyte-like cells derived from preterm WJ-MSCs may be used as a bridging 
therapy for end-stage liver diseases, since they can provide mature hepatocyte 
functions, coupled to key immunomodulatory activities. This may be relevant also in 
the restoration of physiological conditions in an organ severely impaired by the 
underlying disease. One of the effects of these cells in vivo may be the reactivation of 
local progenitors, and therefore the stimulation of the self-reparative mechanisms that 
physiologically take place in liver at higher levels with respect to other organs. In our 
opinion, the data obtained in this project may be complemented by the development 
of an in vivo model of end-stage liver disease to verify the effectiveness of our 
hypothesis. 
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